Granulocyte-Macrophage Colony-Stimulating Factor as a Therapeutic Target in Multiple Sclerosis

Multiple sclerosis is an inflammatory neurodegenerative disease of the central nervous system (CNS) and the most frequent cause of non-traumatic disability in adults in the Western world. Currently, several drugs have been approved for the treatment of multiple sclerosis. While the newer drugs are more effective, they have less favourable safety profiles. Thus, there is a need to identify new targets for effective and safe therapies, particularly in patients with progressive disease for whom no treatments are available. One such target is granulocyte-macrophage colony-stimulating factor (GM-CSF) or its receptor. In this article we review data on the potential role of GM-CSF and GM-CSF inhibition in MS. We discuss the expression and function of GM-CSF and its receptor in the CNS, as well as data from animal studies and clinical trials in MS.

• Publication year

  2018

• Venue

  Neurological Therapeutics

• Publication date

  2018-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40120-018-0120-1PMID 30506485PMCID 6534644
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GM-CSF Promotes Chronic Disability in Experimental Autoimmune Encephalomyelitis by Altering the Composition of Central Nervous System–Infiltrating Cells, but Is Dispensable for Disease Induction

  2018cited by this paper
• Multiple sclerosis onset after granulocyte macrophage colony-stimulating factor withdrawal.

  2018cited by this paper
• CCR6+ Th cells in the cerebrospinal fluid of persons with multiple sclerosis are dominated by pathogenic non-classic Th1 cells and GM-CSF-only-secreting Th cells

  2017cited by this paper
• GM-CSF is not essential for experimental autoimmune encephalomyelitis but promotes brain-targeted disease.

  2017cited by this paper
• Targeting the GM-CSF receptor for the treatment of CNS autoimmunity.

  2017cited by this paper
• Elevated expression of granulocyte-macrophage colony-stimulating factor receptor in multiple sclerosis lesions.

  2017cited by this paper
• Commanding CNS Invasion: GM-CSF.

  2017cited by this paper
• Dysregulation of the Cytokine GM‐CSF Induces Spontaneous Phagocyte Invasion and Immunopathology in the Central Nervous System

  2017cited by this paper
• GM-CSF as a therapeutic target in autoimmune diseases

  2016cited by this paper
• Targeting GM-CSF in inflammatory diseases

  2016cited by this paper
• Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy

  2015cited by this paper
• GM‐CSF promotes migration of human monocytes across the blood brain barrier

  2015cited by this paper
• Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy

  2015cited by this paper
• The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses Autoimmunity.

  2015cited by this paper
• GM-CSF in Neuroinflammation: Licensing Myeloid Cells for Tissue Damage.

  2015cited by this paper
• IL‐12‐polarized Th1 cells produce GM‐CSF and induce EAE independent of IL‐23

  2015cited by this paper
• GM-CSF production by CD4+ T cells in MS patients: regulation by regulatory T cells and vitamin D.

  2015cited by this paper
• Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis

  2015cited by this paper
• STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation

  2014cited by this paper
• Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis

  2014cited by this paper
• MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial

  2014cited by this paper
• Secretome Analysis of Human Oligodendrocytes Derived from Neural Stem Cells

  2014cited by this paper
• IL-1β Promotes the Differentiation of Polyfunctional Human CCR6+CXCR3+ Th1/17 Cells That Are Specific for Pathogenic and Commensal Microbes

  2014cited by this paper
• IL-17 and GM-CSF Expression Are Antagonistically Regulated by Human T Helper Cells

  2014cited by this paper
• Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells

  2014cited by this paper
• Inflammasome-derived IL-1{beta} regulates the production of GM-CSF by CD4+ T cells and {gamma}{delta} T cells

  2012cited by this paper
• Cutting Edge: Suppression of GM-CSF Expression in Murine and Human T Cells by IL-27

  2012cited by this paper
• GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells.

  2012cited by this paper
• Inflammasome-Derived IL-1β Regulates the Production of GM-CSF by CD4+ T Cells and γδ T Cells

  2012cited by this paper
• RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation

  2011cited by this paper
• The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF

  2011cited by this paper
• Cutting Edge: Granulocyte-Macrophage Colony-Stimulating Factor Is the Major CD8+ T Cell-Derived Licensing Factor for Dendritic Cell Activation

  2010cited by this paper
• EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo.

  2010cited by this paper
• GM-CSF-facilitated dendritic cell recruitment and survival govern the intestinal mucosal response to a mouse enteric bacterial pathogen.

  2010cited by this paper
• EAE mediated by a non‐IFN‐γ/non‐IL‐17 pathway

  2010cited by this paper
• The molecular basis of pulmonary alveolar proteinosis.

  2010cited by this paper
• Granulocyte macrophage colony stimulating factor (GM-CSF) biological actions on human dermal fibroblasts.

  2009cited by this paper
• Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease.

  2009cited by this paper
• GM-CSF mediates autoimmunity by enhancing IL-6–dependent Th17 cell development and survival

  2008cited by this paper
• G-CSF and GM-CSF concentrations and receptor expression in peripheral blood leukemic cells from patients with chronic myelogenous leukemia.

  2008cited by this paper
• Colony-stimulating factors in inflammation and autoimmunity

  2008cited by this paper
• In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification.

  2008cited by this paper
• The role of granulocyte macrophage-colony-stimulating factor in acute intestinal inflammation

  2008cited by this paper
• Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on lung cancer: roles of cyclooxygenase-2.

  2007cited by this paper
• GM-CSF Production by Autoreactive T Cells Is Required for the Activation of Microglial Cells and the Onset of Experimental Autoimmune Encephalomyelitis1

  2007cited by this paper
• Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.

  2006cited by this paper
• Granulocyte-macrophage colony-stimulating factor regulates effector differentiation of invariant natural killer T cells during thymic ontogeny.

  2006cited by this paper
• Granulocyte macrophage colony-stimulating factor expression by both renal parenchymal and immune cells mediates murine crescentic glomerulonephritis.

  2005cited by this paper
• GM-CSF Induction in Human Lung Fibroblasts by IL-1β, TNF-α, and Macrophage Contact

  2003cited by this paper
• Effect of granulocyte-macrophage colony-stimulating factor on natural-killer cell mediated cytotoxicity.

  2003cited by this paper
• GM-CSF induction in human lung fibroblasts by IL-1beta, TNF-alpha, and macrophage contact.

  2003cited by this paper
• Local delivery of granulocyte macrophage colony-stimulating factor by retrovirally transduced antigen-specific T cells leads to severe, chronic experimental autoimmune encephalomyelitis in mice.

  2002cited by this paper
• Granulocyte-Macrophage Colony-Stimulating Factor Induces an Expression Program in Neonatal Microglia That Primes Them for Antigen Presentation1

  2002cited by this paper
• Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset

  2001cited by this paper
• Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.

  2001cited by this paper
• Local Transgenic Expression of Granulocyte Macrophage-Colony Stimulating Factor Initiates Autoimmunity1

  2001cited by this paper
• Effect of granulocyte macrophage colony‐stimulating factor in a patient with benign systemic mastocytosis

  2001cited by this paper
• Distinct domains of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit mediate activation of Jak/Stat signaling and differentiation.

  2001cited by this paper
• Granulocyte Macrophage Colony-Stimulating Factor

  2001cited by this paper
• Granulocyte Macrophage Colony-Stimulating Factor A New Putative Therapeutic Target in Multiple Sclerosis

  2001cited by this paper
• IL-10 Inhibits Granulocyte-Macrophage Colony-Stimulating Factor-Dependent Human Monocyte Survival at the Early Stage of the Culture and Inhibits the Generation of Macrophages1

  2001cited by this paper
• Microbial Lipopeptides Induce the Production of IL-17 in Th Cells1

  2000cited by this paper
• Granuloctye-Macrophage Colony-Stimulating Factor as an Autocrine Survival Factor for Mature Normal and Malignant B Lymphocytes1

  2000cited by this paper
• Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity.

  1998cited by this paper
• Granulocyte-macrophage colony-stimulating factor crosses the blood--brain and blood--spinal cord barriers.

  1997cited by this paper
• Granulocyte macrophage-colony stimulating factor crosses the blood-testis barrier in mice.

  1997cited by this paper
• Activation of JAK2 in human vascular endothelial cells by granulocyte-macrophage colony-stimulating factor.

  1997cited by this paper
• Suppression by IL-10 and IL-4 of cytokine production induced by two-way autologous mixed lymphocyte reaction.

  1996cited by this paper
• Epithelial cells are the major source of biologically active granulocyte macrophage colony-stimulating factor in human endometrium.

  1995cited by this paper
• Roles of the cytoplasmic domains of the alpha and beta subunits of human granulocyte-macrophage colony-stimulating factor receptor.

  1995cited by this paper
• Roles of the cytoplasmic domains of the α and β subunits of human granulocyte-macrophage colony-stimulating factor receptor

  1995cited by this paper
• GM-CSF activates regenerative epidermal growth and stimulates keratinocyte proliferation in human skin in vivo.

  1994cited by this paper
• GM‐CSF promotes proliferation of human fetal and adult microglia in primary cultures

  1994cited by this paper
• Coordinate and noncoordinate colony stimulating factor formation by human monocytes

  1994cited by this paper
• Expression of cytokine receptors in cultured neuronal and glial cells.

  1993cited by this paper
• Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage colony-stimulating factor production in human arterial smooth muscle cells.

  1993cited by this paper
• Production of granulocyte-macrophage colony-stimulating factor by cultured human tracheal epithelial cells.

  1992cited by this paper
• Interleukin-5, interleukin-3, and granulocyte-macrophage colony-stimulating factor cross-compete for binding to cell surface receptors on human eosinophils.

  1991cited by this paper
• Transforming growth factor-beta trans-modulates the expression of colony stimulating factor receptors on murine hematopoietic progenitor cell lines.

  1991cited by this paper
• Human articular cartilage and chondrocytes produce hemopoietic colony-stimulating factors in culture in response to IL-1.

  1991cited by this paper
• Production of hemopoietic colony-stimulating factors by astrocytes.

  1990cited by this paper
• Inhibition of human macrophage colony formation by interleukin 4

  1989cited by this paper
• Myeloid haemopoietic growth factors.

  1989cited by this paper
• Nonhematopoietic tumor cells express functional GM-CSF receptors.

  1989cited by this paper
• Nonhematopoietic tumor cells express functional GM-CSF receptors

  1989cited by this paper
• Human granulocyte-macrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhemopoietic origin.

  1988cited by this paper
• Synergistic activation of human monocytes by granulocyte-macrophage colony-stimulating factor and IFN-gamma. Increased TNF-alpha but not IL-1 activity.

  1988cited by this paper
• Keratinocyte growth regulation by the products of immune cells

  1988cited by this paper
• Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones.

  1987cited by this paper
• Interleukin 1 stimulates granulocyte macrophage colony-stimulating activity release by vascular endothelial cells.

  1986cited by this paper
• Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

  1986cited by this paper
• Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes.

  1986cited by this paper
• Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2.

  1986cited by this paper
• Materials and Methods Brief Definitive Report Granulocyte/macrophage Colony-stimulating Factor and Interleukin 3 Release from Human Peripheral Blood Eosinophils and Neutrophils

  year unknowncited by this paper

• White matter paramagnetic rim and non-rim lesions share a periventricular gradient in multiple sclerosis: A 7-T imaging study

  2024cites this paper
• Inflammatory Cytokines Associated with Multiple Sclerosis Directly Induce Alterations of Neuronal Cytoarchitecture in Human Neurons

  2023cites this paper
• Blockade of Proteinase-Activated Receptor 2 (PAR2) Attenuates Neuroinflammation in Experimental Autoimmune Encephalomyelitis

  2023cites this paper
• Oleacein: A comprehensive review of its extraction, purification, absorption, metabolism, and health effects.

  2023cites this paper
• The Role of the Proinflammatory and Anti-inflammatory Cytokines in Multiple Sclerosis

  2022cites this paper
• Elevated proportion of TLR2- and TLR4-expressing Th17-like cells and activated memory B cells was associated with clinical activity of cerebral cavernous malformations

  2022cites this paper
• Reversing Radiation-Induced Immunosuppression Using a New Therapeutic Modality

  2022cites this paper
• Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy

  2022cites this paper
• Identifying an Optimal Neuroinflammation Treatment Using a Nanoligomer Discovery Engine.

  2022cites this paper
• Screening Immunotherapy Targets to Counter Radiation-Induced Neuroinflammation

  2022cites this paper
• The many-sided contributions of NF-κB to T-cell biology in health and disease.

  2021cites this paper
• Neurological risks and benefits of cytokine‐based treatments in coronavirus disease 2019: from preclinical to clinical evidence

  2021influential citation
• Glatiramer acetate increases T- and B -regulatory cells and decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) in an animal model of multiple sclerosis.

  2020cites this paper
• Oleacein Attenuates the Pathogenesis of Experimental Autoimmune Encephalomyelitis through Both Antioxidant and Anti-Inflammatory Effects

  2020cites this paper
• Potential for Targeting Myeloid Cells in Controlling CNS Inflammation

  2020cites this paper
• The Microbiome as a Therapeutic Target for Multiple Sclerosis: Can Genetically Engineered Probiotics Treat the Disease?

  2020cites this paper
• Prospective evaluation of host biomarkers other than interferon gamma in QuantiFERON Plus supernatants as candidates for the diagnosis of tuberculosis in symptomatic individuals.

  2019cites this paper
• Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update

  2019cites this paper